Sumit K. Subudhi, M.D., Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Sumit Subudhi is a medical oncologist and immunologist whose research focuses on the mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. Dr. Subudhi’s medical training began when he enrolled in the MD/PhD program at The University of Chicago Pritzker School of Medicine in 1998. Dr. Subudhi’s predoctoral studies included examining the role of B7-H1 (PD-L1), an immune checkpoint, in regulating T cell–mediated immune responses. He completed his PhD in 2004, his MD in 2007, his internal medicine residency at the New York-Presbyterian Hospital/Weill Cornell Medical Center in 2009, and his medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in 2013. During his medical training, Dr. Subudhi became interested in the field of tumor immunology and subsequently completed a postdoctoral fellowship in Dr. James P. Allison’s laboratory at MSKCC. In Dr. Allison’s laboratory (now at MD Anderson), Dr. Subudhi began to examine the effects of targeting immune checkpoints (e.g., CTLA-4 and PD-1) in prostate cancer and continues to uncover the mechanisms that tumors use to evade the immune system.
After completing his fellowship at MSKCC, Dr. Subudhi was appointed as an Advanced Scholar Instructor at MD Anderson Cancer Center in 2013, and more recently (2014) as an Assistant Professor in Genitourinary Medical Oncology. His focus is on investigating optimal combinations of immune checkpoint blockade-based therapies and on developing immunological biomarkers to predict treatment responses, with the hope of ultimately producing durable and even curative responses in patients with prostate cancer. Dr. Subudhi was awarded the Prostate Cancer Foundation Young Investigator Award in 2014 to pursue these studies. Dr. Subudhi has also been investigating the immunological differences between primary prostate cancer and the bone metastasis microenvironment.
Education & Training
Degree-Granting Education
| 2007 | The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, US, MD |
| 2004 | The University of Chicago, Division of Biological Sciences, Chicago, Illinois, US, Immunology, PhD |
| 1994 | The University of Pennsylvania, College of Arts and Sciences, Philadelphia, Pennsylvania, US, Biological Basis of Behavior, BA |
Postgraduate Training
| 2009-2013 | Clinical Fellowship, Medical Oncology Fellowship, Memorial Sloan-Kettering Cancer Center, New York, New York |
| 2007-2009 | Clinical Residency, Internal Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York |
Board Certifications
| 2013 | American Board of Internal Medicine-Medical Oncology |
| 2010 | American Board of Internal Medicine-Internal Medicine |
Experience & Service
Academic Appointments
Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 2014 - 2021
Advanced Scholar Instructor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2014
Other Appointments/Responsibilities
Advisory Board Member, Regeneron, 2024 - 2024
Advisory Board Member, Macrogenics, 2024 - 2024
Advisory Board Member, Merck, Detroit, MI, 2023
Advisory Board Member, Bristol-Myers Squibb, Maryland, 2023
Advisory Board Member, Merck AZ US Prostate Cancer Team, Detroit, MI, 2023
Advisory Board Member, Regeneron, San Francisco, CA, 2023
Advisory Board Member, Bristol-Myers Squibb, San Francisco, CA, 2023
Advisory Board Member, Janssen, Virtual, 2022
Advisory Board Member, Janssen, New Orleans, LA, 2022
Advisory Board Member, Bayer, Virtual, 2021
Advisory Board Member, Astellas/Pfizer, Virtual, 2021
Advisory Board Member, Dendreon, Virtual, 2021
Advisory Board Member, Chemocentryx, Virtual, 2021
TMB Advisory Board Member, Bristol-Myers Squibb, Virtual, 2021
Advisory Board Member, Janssen, Virtual, 2021
Advisory Board Member, Amgen, Virtual, 2020
Advisory Board Leader, Dendreon, Houston, TX, 2019
Advisory Board Leader, Dendreon, Miami, FL, 2019
Advisory Board Member, Bristol-Myers Squibb, Barcelona, Spain, 2019
Advisory Board Member, Amgen, Phoenix, AZ, 2019
Advisory Board Member, Bayer, Raleigh, NC, 2019
Advisory Board Leader, Dendreon, Pittsburg, PA, 2019
Advisory Board Member, Bayer, San Francisco, CA, 2019
Advisory Board Member, Janssen, Houston, TX, 2018
Advisory Board Member, Compugen, Chicago, IL, 2018
Advisory Board Member, Janssen, Chicago, IL, 2018
Advisory Board Member, Compugen, Chicago, IL, 2017
Advisory Board Member, Dendreon, Chicago, IL, 2016
Advisory Board Member, Dendreon, Chicago, IL, 2015
Advisory Board Member, Dendreon, Wichita, KS, 2015
Institutional Committee Activities
Deputy Lead, MD Anderson Clinical Immunology Working Group, 2025 - Present
Co-Lead, Essential Biomarkers Taskforce Development, 2025 - Present
Member, Scientific Advisory Board, 2025 - Present
Member, Board of Directors, 2024 - Present
Member, Committee on Immuno-Oncology, 2024 - Present
Member, Scientific Advisory Board, 2024 - Present
Co-Chair, MD Anderson Cancer Center Immuno-Oncology Toxicity (IOTOX) Research Committee, 2024 - Present
Member, Scientific Advisory Board, 2021 - Present
Departmental Representative, MD Anderson Cancer Center Faculty Senate, 2021 - Present
Member, Scientific Advisory Board, 2021 - 2023
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, 2021 - Present
Executive Committee Member, MD Anderson Cancer Center Institutional Immuno-Oncology Toxicity (IOTOX) Initiative, 2020 - 2024
Co-Chair, MD Anderson Clinical Immunology Working Group, 2020 - 2024
Member, Safety Monitoring Committee for DSP107 Study (NCT04440735), 2020 - Present
Co-Leader, MD Anderson Cancer Center Immuno-Oncology Toxicity (IOTOX) Initiative Working Group, 2019 - Present
Co-Leader, MD Anderson Cancer Center Department of Genitourinary Medical Oncology Immuno-Oncology Toxicity (IOTOX) Group, 2019 - Present
Leader, Prostate Researching Translational Endpoints Correlated to Response (PORTER), 2019 - 2022
Member, Safety Assessment Committee for Prostate Researching Translational Endpoints Correlated to Response (PORTER),, 2019 - 2022
Executive Committee Member, MD Anderson Cancer Center Clinical Immunology Working Group, 2019 - Present
Leader, MD Anderson Cancer Center Department of Genitourinary Medical Oncology Prostate Cancer Clinical Trial Priorities, 2019 - Present
Chairperson, Drug Selection Committee for Prostate Researching Translational Endpoints Correlated to Response (PORTER), 2019 - 2022
Flagship Co-Leader, MD Anderson Prostate Cancer Moon Shot Program, 2019 - 2024
Chairperson, Independent Data Monitoring Committee (IDMC) for ProVent Study (NCT03686683), 2018 - Present
Member, MD Anderson Clinical Immunology Working Group, 2017 - 2019
Member, MD Anderson Scientific Research Committee (SRC), 2016 - Present
Honors & Awards
| 2023 | Regeneron-PCF Special Challenge Award, Prostate Cancer Foundation (PCF) |
| 2017 | Lloyd Family Clinical Oncology Scholar Award, V Foundation |
| 2014 | Young Investigator Award, Prostate Cancer Foundation |
| 2013 | Advanced Scholar, The University of Texas MD Anderson Cancer Center |
| 2011 | ASCO Poster Discussion Session, American Society of Clinical Oncology |
| 2011 | NIH Loan Repayment Program, National Institutes of Health |
| 2011 | NIH Clinical Scholars Biomedical Research Training Program, National Institutes of Health |
| 2006 | Francis L. Lederer MD/PhD Scholars Research Grant, University of Chicago |
| 2004 | Doolittle - Harrison Travel Fellowship, University of Chicago |
| 2002 | Best Poster Presentation, University of Chicago |
| 2000 | Winner, Sixth Annual Medical Student Poster Competition, American Society of Internal Medicine |
| 2000 | NIH Pediatric Growth and Development Training Grant, National Institutes of Health |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Di Giacomo AM, Subudhi S, Vos W, Andreatta M, Carmona S, McTavish W, Seliger B, Ibrahim R, Lahn M, Smith M, Eggermont A, Fox BA, Maio M. Perspectives on the role of "-Omics" in predicting response to immunotherapy. Eur J Cancer 220:115393, 2025. e-Pub 2025. PMID: 40168935.
- Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM, Cillo AR, Collyar D, Cope L, Deutsch JS, Dubrovsky G, Gnjatic S, Goh D, Halabi S, Kohanbash G, Maecker HT, Maleki Vareki S, Mullin S, Seliger B, Taube J, Vos W, Yeong J, Anderson KG, Bruno TC, Chiuzan C, Diaz-Padilla I, Garrett-Mayer E, Glitza Oliva IC, Grandi P, Hill EG, Hobbs BP, Najjar YG, Pettit Nassi P, Simons VH, Subudhi SK, Sullivan RJ, Takimoto CH. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer 13(3), 2025. e-Pub 2025. PMID: 40054999.
- Galsky MD, Autio KA, Cabanski CR, Wentzel K, Graff JN, Friedlander TW, Howes TR, Shotts KM, Densmore J, Spasic M, Da Silva DM, Chen RO, Lata J, Skolnik J, Keler T, Yellin MJ, LaVallee TM, Fairchild J, Boffo S, O'Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi SK, Fong L. Clinical and translational results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer. Clin Cancer Res, 2025. e-Pub 2025. PMID: 39964352.
- Stein MN, Dumbrava EE, Teply BA, Gergis US, Guiterrez ME, Reshef R, Subudhi SK, Jacquemont CF, Senesac JH, Bayle JH, Scripture CD, Chatwal MS, Bilen MA, Stadler WM, Becerra CR. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: A phase 1 dose escalation trial. Nat Commun 15(1):10743, 2024. e-Pub 2024. PMID: 39737899.
- Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer 31(12), 2024. e-Pub 2024. PMID: 39324992.
- Ali, A, Lu, Y, Khalaf, SZ, Iliescu, C, Koutroumpakis, E, Yusuf, SW, Siddiqui, BA, Subudhi, SK, Deswal, A, Palaskas, NL. Use of positron emission tomography for the diagnosis of immune-checkpoint inhibitor| myocarditis. Journal of Nuclear Cardiology 39, 2024. e-Pub 2024. PMID: 39053574.
- Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, Allison JP, Sheth RA, Tummala S, Buja M, Bhattacharjee MB, Iliescu C, Rawther-Karedath A, Deswal A, Wang L, Sharma P, Subudhi SK. Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis. Cancer Immunol Res 12(8):964-987, 2024. e-Pub 2024. PMID: 38768394.
- Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. e-Pub 2024. PMID: 39019979.
- Jiang Y, Montierth MD, Yu K, Ji S, Guo S, Tran Q, Liu X, Shin SJ, Cao S, Li R, Tang Y, Lesluyes T, Kopetz S, Ajani J, Msaouel P, Subudhi SK, Aparicio A, Sharma P, Shen JP, Sood AK, Tarabichi M, Wang JR, Kimmel M, Loo PV, Zhu H, Wang W. Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcome. bioRxiv, 2024. e-Pub 2024. PMID: 39005348.
- Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilié PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A modular trial of androgen signaling inhibitor combinations testing a risk-adapted strategy in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
- Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee C, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res 30(10):2272-2285, 2024. e-Pub 2024. PMID: 38488813.
- Ghosh S, Padhi R, Sahu S, Meher M, Jain P, Subudhi SK, Vihari J, Samal A, Sahu AK. Use of inferior vena cava guided fluid therapy in the treatment of septic shock: A randomised controlled trial. J Infect Dev Ctries 18(1):75-81, 2024. e-Pub 2024. PMID: 38377091.
- Viscuse PV, Slack-Tidwell RS, Zhang M, Rohra P, Zhu K, San Lucas FA, Konnick E, Pilie PG, Siddiqui B, Logothetis CJ, Corn P, Subudhi SK, Pritchard CC, Soundararajan R, Aparicio A. Evaluation of the aggressive-variant prostate cancer molecular signature in clinical laboratory improvement amendments (CLIA) environments. Cancers (Basel) 15(24), 2023. e-Pub 2023. PMID: 38136389.
- Hahn AW, Thoman W, Koutroumpakis E, Abdulla A, Subudhi SK, Aparicio A, Basen-Enngquist K, Logothetis CJ, Gilchrist SC. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology 9(1):33, 2023. e-Pub 2023. PMID: 37705024.
- Antonarakis ES, Subudhi SK, Pieczonka CM, Karsh LI, Quinn DI, Hafron JM, Wilfehrt HM, Harmon M, Sheikh NA, Shore ND, Petrylak DP. Combination treatment with sipuleucel-t and abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer: STAMP and STRIDE trials. Clin Cancer Res 29(13):2426-2434, 2023. e-Pub 2023. PMID: 37058234.
- Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
- Drake, CG, Pachynski, RK, Subudhi, SK, McNeel, DG, Antonarakis, ES, Bauer, TM, Lauer, P, Brockstedt, D, Patricia, D, Wade, M, Zudaire, E, Bandyopadhyay, N, Parasrampuria, DA, Girgis, S, Mason, G, Knoblauch, RE, Stone, N, Infante, JR, Gottardis, MM, Fong, L. Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 25(2):219-228, 2022. e-Pub 2022. PMID: 34257408.
- Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. Eur J Cancer 157:259-267, 2021. e-Pub 2021. PMID: 34536949.
- Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, Durand JB, Deswal A, Zhao B, Buja LM, Iliescu C. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 23(10):1725-1735, 2021. e-Pub 2021. PMID: 34114291.
- Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10), 2021. e-Pub 2021. PMID: 34663638.
- Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of technology-enabled monitoring of patient-reported outcomes to detect and treat toxic effects linked to immune checkpoint inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
- Charles G Drake, Russell K Pachynski, Sumit K Subudhi, Douglas G McNeel, Emmanuel S Antonarakis, Todd M Bauer, Peter Lauer, Dirk Brockstedt, Daniel Patricia, Mark Wade, Enrique Zudaire, Nibedita Bandyopadhyay, Dolly A Parasrampuria, Suzette Girgis, Gary E Mason, Roland E Knoblauch, Nicole Stone, Jeffrey R Infante, Marco M Gottardis, Lawrence Fong. Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Disease, 2021. e-Pub 2021. PMID: 34257408.
- Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable Responses in Patients with Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge after Moderate to Severe Immune-Related Adverse Events. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
- Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer 28(7):419-431, 2021. e-Pub 2021. PMID: 33890870.
- Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res 27(11):3253-3264, 2021. e-Pub 2021. PMID: 33753455.
- Chang KY, Chiang NJ, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu K, Johnston A, Bomalaski JS, Wu BW, Gao J, Subudhi SK, Kaseb AO, Blando JM, Yadav SS, Szlosarek PW, Chen LT. Phase 1b Study of Pegylated Arginine Deiminase (ADI-PEG 20) plus Pembrolizumab in Advanced Solid Cancers OncoImmunology. OncoImmunology 10(1), 2021. e-Pub 2021. PMID: 34290906.
- Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer 9(5), 2021. e-Pub 2021. PMID: 33986125.
- Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 19(1):22-31, 2021. e-Pub 2021. PMID: 32675015.
- Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell 38(4):489-499.e3, 2020. e-Pub 2020. PMID: 32916128.
- Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
- Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
- Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127:67-75, 2020. e-Pub 2020. PMID: 31986451.
- Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in tumor microenvironment dictate t helper lineage polarization and response to immune checkpoint therapy. Cell 179(5):1177-1190.e13, 2019. e-Pub 2019. PMID: 31730856.
- Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Scutti JB, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P. Characterization and comparison of GITR expression in solid tumors. Clin Cancer Res 25(21):6501-6510, 2019. e-Pub 2019. PMID: 31358539.
- Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246-22251, 2019. e-Pub 2019. PMID: 31611368.
- Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol 37(30):JCO1900320, 2019. e-Pub 2019. PMID: 31163011.
- Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
- Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin Cancer Res 25(4):1233-1238, 2019. e-Pub 2019. PMID: 30054281.
- Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. Inflamm Bowel Dis 25(2):385-393, 2019. e-Pub 2019. PMID: 30169584.
- Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188, 2019. e-Pub 2019. PMID: 30479380.
- Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. PMID: 30420754.
- Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid 28(10):1243-1251, 2018. e-Pub 2018. PMID: 30132401.
- Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818, 2018. e-Pub 2018. PMID: 29905573.
- Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol 80(3):583-589, 2017. e-Pub 2017. PMID: 28730293.
- Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555, 2017. e-Pub 2017. PMID: 28346412.
- Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
- Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+a-PD-1 therapy. Nat Commun 7:12335, 2016. e-Pub 2016. PMID: 27498556.
- Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36, 2016. e-Pub 2016. PMID: 27330809.
- Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32, 2014. e-Pub 2014. PMID: 24598590.
- Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309-22, 2013. e-Pub 2013. PMID: 24315100.
- Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res 19(22):6112-25, 2013. e-Pub 2013. PMID: 24081977.
- Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 13(11):1105-13, 2012. e-Pub 2012. PMID: 23059047.
- Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol 175(2):1295-300, 2005. e-Pub 2005. PMID: 16002734.
- Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest 115(3):711-7, 2005. e-Pub 2005. PMID: 15696194.
- Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A 101(39):14198-203, 2004. e-Pub 2004. PMID: 15375218.
- Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre ML, Fu YX. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 113(5):694-700, 2004. e-Pub 2004. PMID: 14991067.
- Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171(7):3348-52, 2003. e-Pub 2003. PMID: 14500627.
- Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8(12):1405-13, 2002. e-Pub 2002. PMID: 12426559.
- Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. The Src family kinase Fyn mediates signals induced by TCR antagonists. J Immunol 168(9):4480-7, 2002. e-Pub 2002. PMID: 11970992.
- Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 168(3):1457-65, 2002. e-Pub 2002. PMID: 11801689.
- Tesciuba AG, Subudhi SK, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis LA, Bluestone JA, Sperling AL. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunology 167(4):1996-2003, 2001. e-Pub 2001. PMID: 11489981.
- Cassel DL, Subudhi SK, Surrey S, McKenzie SE. GATA and NF-Y participate in transcriptional regulation of FcgammaRIIA in megakaryocytic cells. Blood Cells Mol Dis 26(6):587-97, 2000. e-Pub 2000. PMID: 11112392.
Invited Articles
- Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a strategic initiative at MD Anderson Cancer Center to improve outcomes in immune-related adverse events. J Natl Compr Canc Netw 22(5), 2024. e-Pub 2024. PMID: 38190801.
- Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652-1669, 2023. e-Pub 2023. PMID: 37059068.
- Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med 3(4):2666-3791, 2022. e-Pub 2022. PMID: 35492243.
- Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40(3):249-251, 2022. e-Pub 2022. PMID: 35290784.
- Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci 1489(1):30-47, 2021. e-Pub 2021. PMID: 33184911.
- Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. e-Pub 2021. PMID: 33811120.
- Subudhi SK. New approaches to immunotherapy for metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol 17(5):283-286, 2019. e-Pub 2019. PMID: 31188806.
- Sheth RA, Perkons N, Dondossola E, Subudhi SK, Gade TP, Tam AL. Patient-derived xenograft tumor models: overview and relevance to IR. J Vasc Interv Radiol 29(6):880-882.e1, 2018. e-Pub 2018. PMID: 29798759.
- Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus 4(3):442-454, 2018. e-Pub 2018. PMID: 29056275.
- Laccetti AL, Subudhi SK. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?. Curr Opin Urol 27(6):566-571, 2017. e-Pub 2017. PMID: 28825923.
- Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Beyond seed and soil: understanding and targeting metastatic prostate cancer; report from the 2016 coffey-holden prostate cancer academy meeting. Prostate 77(2):123-144, 2017. e-Pub 2017. PMID: 27679977.
- Goswami S, Aparicio A, Subudhi SK. Immune checkpoint therapies in prostate cancer. Cancer J 22(2):117-20, 2016. e-Pub 2016. PMID: 27111907.
- Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43):5411-5417, 2015. e-Pub 2015. PMID: 25659583.
- Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: co-stimulation verse co-inhibition. J Mol Med (Berl) 83(3):193-202, 2005. e-Pub 2005. PMID: 15630593.
- Sun Y, Subudhi SK, Fu YX. Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends Mol Med 9(11):483-9, 2003. e-Pub 2003. PMID: 14604826.
Other Articles
- Kim ST, Murphy WA Jr, Aparicio A, Subudhi SK RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. J Immunother Precis Oncol 3(3):128-132, 2020. PMID: 35663254.
- Shannon VR, Subudhi SK, Huo L, Faiz SA Diffuse alveolar hemorrhage with nivolumab monotherapy. Respir Med Case Rep 30:101131, 2020. PMID: 32577370.
Editorials
- Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res 25(11):3469-3470, 2019.
- Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology 217(6):590-2, 2012. PMID: 22459268.
- Subudhi SK, Callahan MK, Wolchok JD. Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park) 24(14):1288, 1294, 2010. PMID: 21294472.
Abstracts
- Subudhi SK, Hauke RJ, Call JA, Sun J, Casey D, Wei XX. LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC). American Society of Clinical Oncology, Genitourinary Cancers Symposium 2024, 2024. e-Pub 2024.
- Siddiqui BA, Palaskas N, Basu S, He Z, Sheth R, Buja M, Bhattacharjee M, Mancuso J, Fu T, Iliescu C, Deswal A, Rawther-Karedath A, Yadav SS, Allison JP, Sharma P, Subudhi SK. Identifying molecular targets for rational immunosuppressive strategies in severe immune checkpoint therapy (ICT)-induced myocarditis and myositis. American Society for Clinical Oncology (ASCO) Annual Meeting 2023, 2023. e-Pub 2023.
- Pilié PG, Tidwell RS, Viscuse PV, Subudhi SK, Corn PG, Tu S, Araujo JC, Zurita AJ, Wang J, Efstathiou E, Deinert J, Logothetis C, Thompson TC, Aparicio A. Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC), 2023. e-Pub 2023.
- Hahn AW, Tidwell RS, Thoman W, Abdulla A, Koutroumpakis E, Aparicio A, Subudhi SK, Siddiqui BA, Pilié PG, Zurita AJ, Corn PG, Laccetti AL, Jana BR, Basen-Engquist K, Logothetis C. A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio). Journal of Clinical Oncology, Genitourinary Cancer Symposium 2023, 2023. e-Pub 2023.
- Palaskas NL, Lu Y, Caldwell R, Oderinde P, Pina G, Ali A, Shah K, Iliescu C, Yusuf SW, Koutroumpakis E, Khalaf S, Hamzeh I, Siddiqui BA, Subudhi SK, Deswal A. Use of positron emission tomography for the diagnosis of immune checkpoint inhibitor myocarditis. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2022. e-Pub 2022.
- Caldwell R, Pina G, Oderinde P, Ali A, Garrett J, Siddiqui BA, Subudhi SK, Iliescu C, Yusuf SW, Koutroumpakis E, Hamzeh E, Khalaf S, Deswal A, Palaskas NL. Elevated serum TNF-α is a candidate prognostic biomarker for immune checkpoint inhibitor myocarditis. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2022. e-Pub 2022.
- Hahn AW, Siddiqui, BA, Logothetis CJ, Subudhi SK, Corn PG, Pilie P, Zurita AJ, Aparicio AM, Tidwell, R S, Thoman, W, Abdulla, A, Koutroumpakis, E, Laccetti, A L, Jana, B, Basen-Engquist, K. A phase II trial modifying metabolic syndrome and cardiovascular risk for prostate cancer patients on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio). American Society for Clinical Oncology (ASCO), 2022. e-Pub 2022.
- Siddiqui BA, Palaskas N, Sheth R, Basu S, Tummala S, Lu HL, Hosing C, Rawther-Karedath A, Yadav SS, Sharma P, Subudhi SK. Identifying molecular targets for rational immunosuppressive strategies in severe immune checkpoint therapy (ICT)-induced myocarditis, myositis, and myasthenia gravis (MG). International Cancer Immunotherapy Conference (CICON) 2022, 2022. e-Pub 2022.
- Subudhi SK, Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Pettaway C, Ward JF, Tidwell RS, Corn PG, Logothetis CJ, Knoblauch RE, Hutnick NA, Gottardis MM, Drake CG, Allison JP, Sharma P. Daratumumab (anti-cd38) but not edicotinib (csf-1r inhibitor) demonstrates target engagement within the primary prostate cancer, bone marrow and systemic circulation of patients with localized disease. International Cancer Immunotherapy Conference (CICON) 2022, 2022. e-Pub 2022.
- Palaskas NL, Siddiqui BA, Shah K, Koutroumpakis E, Iliescu C, Subudhi SK, Deswal A. Upfront immunomodulatory treatment of immune checkpoint inhibitor myocarditis. American College of Cardiology (ACC) Annual Meeting, 2022. e-Pub 2022.
- Hahn AW, Wang X, Efstathiou E, Hwang H, Zurita AJ, Wang J, Araujo JC, Pilie P, Siddiqui BA, Subudhi SK, Corn PG, Aparicio AM, Tu SM, Logothetis CJ. Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone naïve prostate cancer (M0HNPC). American Society for Clinical Oncology (ASCO), 2022. e-Pub 2022.
- Viscuse P, Tidwell R, Liu J, Guo S, Vundavilli H, Zhang M, Subudhi S, Zurita A, Corn P, Tu S, Araujo J, Wang J, Efstathiou E, Wang J, Pilié P, Troncoso P, Zhang J, Wang W, Logothetis C, Aparicio A. DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC. American Society for Clinical Oncology (ASCO), 2022. e-Pub 2022.
- Siddiqui BA, Chapin BF, Jindal S, Duan F, Yadav SS, Pettaway C, Ward JF, Tidwell RS, Corn PG, Logothetis CJ, Allison JP, Sharma P, Subudhi SK. Target modulation within the tumor microenvironment (TME) by daratumumab (anti-cd38) but not edicotinib (CSF-1r inhibitor) in men with high-risk localized prostate cancer. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2021. e-Pub 2021.
- Efstathiou E, Boukovala MA, Spetsieris N, Wen S, Hoang A, Weldon JA, Tidwell R, Davis JW, Chapin BF, Corn PG, Subudhi SK, Aparicio A, Pettaway CA, Pisters LL, Papadopoulos JN, Adibi M, Wang J, Zurita AJ, Logothetis C, Troncoso P. Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC). Journal of Clinical Oncology, ASCO Annual Meeting 2020, 2020. e-Pub 2020.
- Viscuse PV, Zhang M, Liu J, Tidwell RS, Subudhi SK, Zurita AJ, Corn PG, Tu S, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, Logothetis C, Aparicio A. Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial. Journal of Clinical Oncology, Genitourinary Cancer Symposium 2020, 2020. e-Pub 2020.
- Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, Dorff T, Tagawa ST, Subudhi SK, Antonarakis ES, Armstrong AJ, Petrylak DP, Fizazi K, Salvati ME, Scher HI. A Phase 1 Study of AMG 160, A Half-life Extended Bispecific T Cell Engager (HLE Bite) Immuno-Oncology Therapy Targeting PSMA, in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC). Annals of Oncology, European Society for Medical Oncology 2019, 2019. e-Pub 2019.
- Aparicio A, Zhang M, Ramesh N, Wang X, Corn PG, Zurita AJ, Davis JW, Pettaway CA, Adibi M, Mcguire SE, Tu S, Wang J, Subudhi SK, Elsheshtawi MA, Efstathiou E, Logothetis C, Navin N, Troncoso P, Chapin BF. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). Journal of Clinical Oncology, ASCO Annual Meeting 2019, 2019. e-Pub 2019.
- Siddiqui BA, Durand J, Gao J, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu S, Suarez-Almazor ME, Sudhakar T, Logothetis C, Sharma P, Subudhi SK. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. Journal of Clinical Oncology, ASCO Annual Meeting 2019, 2019. e-Pub 2019.
- Chapin BF, Wang X, Zhang M, Corn PG, Zurita AJ, Elsheshtawi MA, Davis JW, Pettaway CA, Adibi M, Gleave M, Cooperberg MR, Smaldone MC, Mcguire SE, Tu S, Wang J, Subudhi SK, Efstathiou E, Logothetis C, Troncoso P, Aparicio A. Complex biologic heterogeneity of de novo hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment. Journal of Clinical Oncology, ASCO Annual Meeting 2019, 2019. e-Pub 2019.
- Abu-Sbeih H, Ali F, Naqash AR, Owen DH, Patel SH, Otterson GA, Kendra KL, Ricciuti B, Chiari R, Giglio AD, Sleiman J, Funchain P, Beatriz W, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy. Journal of Clinical Oncology, ASCO Annual Meeting 2019, 2019. e-Pub 2019.
- Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Patricia D, Wade M, Zudaire E, Mason G, Knoblauch RE, Stone NL, Infante JR, Gottardis M, Fong L. Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, ASCO Annual Meeting 2019, 2019. e-Pub 2019.
- Subudhi SK, Aparicio A, Zurita AJ, Doger B, Kelly WK, Peer A, Rathkopf DE, Karsh LI, Tryon JJ, Kothari N, Zhao X, Zhu E, Ricci DS, Tran N, De Bono JS. A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350). Journal of Clinical Oncology, ASCO Annual Meeting 2019, 2019. e-Pub 2019.
- Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Duan T, Saci A, Hu S, Han G, Fizazi K. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). Journal of Clinical Oncology, Genitourinary Cancer Symposium 2019, 2019. e-Pub 2019.
- Efstathiou E, Wang X, Zurita AJ, Tu S, Aparicio A, Wang J, Corn PG, Subudhi SK, Araujo JC, Reece LK, Pruitt L, Vanalstine ML, Logothetis C. A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC). Journal of Clinical Oncolocy, ASCO Annual Meeting 2018, 2018. e-Pub 2018.
- Corn PG, Subudhi SK, Araujo JC, Vardaki I, Aparicio A, Tu S, Pagliaro LC, Zurita AJ, Logothetis C, Panaretakis T. Molecular profiling of liquid biopsies from patients (pts) with bone metastatic castration-resistant prostate cancer (BM-CRPC) treated with radium-223 (RA-223) to reveal differential enrichment for markers that correlate with overall survival (OS). Add to Collection. Journal of Clinical Oncology, Genitourinary Oncology Symposium 2018, 2018. e-Pub 2018.
- Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Alstine MV, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). Journal of Clinical Oncology, ASCO Annual Meeting 2017 35, 2017. e-Pub 2017.
- Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu CJ, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, Futreal A, Allison JP, Sharma P. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. Journal of Clinical Oncology, ASCO Annual Meeting 2017 35, 2017. e-Pub 2017.
- Corn PG, Zurita AJ, Subudhi SK, Tu S, Aparicio A, Araujo JC, Kim J, Wang J, Efstathiou E, Pagliaro LC, Logothetis C. Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer. Journal of Clinical Oncology, Genitourinary Oncology Symposium 2017, 2017. e-Pub 2017.
- Odisio BC, Christensen JA, Subudhi SK, Huang S, Gupta S, Ahrar K, Sheth R, Ensor J, Aparicio A. Image guided thermal ablation of prostate cancer metastases to the liver. Journal of Clinical Oncology, ASCO Annual Meeting 2016, 2016. e-Pub 2016.
- Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu CJ, Vence LM, Logothetis CJ, Futreal A, Allison JP, Sharma P. A feasibility study to determine t cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). Journal of Clinical Oncology, ASCO Annual Meeting 2016 34, 2016. e-Pub 2016.
- Subudhi S, Aparicio A, Gao J, Zurita-Saavedra A, Araujo JC, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. Cancer Res, AACR 2016 Annual Meeting, 2016. e-Pub 2016.
- Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo J, Logothetis CJ, Rao B, Vence L, Allison JP, Emerson R, Yusko E, Vignali M, Robins R, Sun J, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in metastatic non-castrate prostate cancer. Prostate Cancer Foundation (PCF) - 22nd Annual Scientific Retreat, 2015. e-Pub 2015.
- Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo J, Logothetis CJ, Rao B, Vence L, Allison JP, Emerson R, Yusko E, Vignali M, Robins H, Sun J, Sharma P. Immune correlates in a phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer. SITC - Society of Immunotherapy, Advances in Cancer Immunotherapy, 2015. e-Pub 2015.
- Corn PG, Tu S, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, ASCO Annual Meeting 2015, 2015. e-Pub 2015.
- Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, Le O, Logothetis C, Aparicio A. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. Journal of Clinical Oncology, ASCO Annual Meeting 2015, 2015. e-Pub 2015.
- Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu S, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in men with hormone-naïve metastatic prostate cancer (HN-mPCa). Annals of Oncology, ESMO, European Society for Medical Oncology 25, 2014. e-Pub 2014.
- Zamarin D, Holmgaard RB, Subudhi SK, Park J, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Journal of Clinical Oncology, ASCO Annual Meeting 2014, 2014. e-Pub 2014.
- Subudhi SK, Montalvo-Ortiz W, Scher HI, Allison JP. Dissecting the therapeutic effects of anti-CTLA-4 and ADT in murine hormone-sensitive prostate cancer. Journal of Clinical Oncology, ASCO Annual Meeting 2013 31, 2013. e-Pub 2013.
- Subudhi SK, Heller G, Danila DC, Anand A, Lacuna KP, Samoila A, Fleisher M, Scher HI. Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer. Journal of Clinical Oncology, ASCO Annual Meeting 2013 31, 2013. e-Pub 2013.
- Oh WK, Kantoff P, Scher HI, Magidson J, Wassmann K, Lee GM, Katz LM, Subudhi SK, Anand A, Fleisher M, Galsky MD, Ross RW. A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology, ASCO Annual Meeting 2012, 2012. e-Pub 2012.
- Subudhi SK, Heller G, Anand A, Danila DC, Fleisher M, Scher HI. A Six-gene Panel that Predicts Survival in Men with Castration-resistant Prostate Cancer. Journal of Clinical Oncology, Genitourinary Cancers Symposium 2013 29, 2011. e-Pub 2011.
Book Chapters
- Sharma P, Anandhan S, Siddiqui BA, Goswami S, Subudhi SK, Gao J, Peggs K, Quezada S, Allison JP. Cancer Immunotherapy. In: Cancer Medicine. 10th, 2020.
- Sharma P, Subudhi S, Peggs S, Goswani S, Gao J, Quezada S, Allison JP. Holland-Frei Cancer Medicine, 9th Edition. In: Chapter 67: Cancer Immunotherapy. 9. Wiley-Blackwell, 2017.
- Subudhi SK, Scher HI, Allison JP. CTLA-4 inhibitors in castration-resistant prostate cancer. In: Targeted Therapies for Castration-Resistant Prostate Cancer. Scardino PT, 2012.
Letters to the Editor
- Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res 25: 3469-3470, 2019.
Selected Presentations & Talks
Local Presentations
- 2023. Promising Immunotherapy Strategies for Advanced Prostate Cancer. Invited. Tex US Too. Houston, TX, US.
- 2022. Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Developments in Immunotherapy for Prostate Cancer, Community Engagement Speaker. Invited. Webinar, US.
- 2020. Developments in Immunotherapy for Prostate Cancer, Community Engagement Speaker. Invited. Indian American Cancer Network (IACAN). Houston, TX, US.
- 2019. Developments in Immunotherapy for Prostate Cancer, Community Engagement Speaker. Invited. Tex Us Too. Houston, TX, US.
- 2018. Immune Checkpoint Therapies in Prostate Cancer. Invited. The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. Boston, MA, US.
- 2018. Overcoming the Immunosuppressive Tumor Microenvironment in Prostate Cancer. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Overcoming the Immunosuppressive Components of the Prostate Cancer Microenvironment to Improve Clinical Outcomes. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Targeting the Immunosuppressive Compartment of the Prostate Cancer Bone Metastatic Microenvironment to Improve Clinical Outcomes. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. myCancerConnection Survivorship Conference. Conference. Medical Panel. Houston, TX, US.
- 2017. Immune Checkpoints: Role in Prostate Cancer Progression and Candidates for Therapeutic Targets. Invited. Regeneron Pharmaceuticals. Tarrytown, NY, US.
- 2017. Immune Checkpoints: Role in Prostate Cancer Progression and Candidates for Therapeutic Targets. Invited. Columbia University Medical Center. New York, NY, US.
- 2017. Tumor Immunology: Past, Present and Future. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Immune Checkpoints: Role in Prostate Cancer Progression & Candidates for Therapeutic Targets. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Rationally Developing Immunotherapy Strategies in Prostate Cancer. Invited. 2016 Cancer Conference: Advancements in Treatment & Technology. Tyler, TX, US.
- 2016. Immunotherapy Advancements. Invited. 2016 Cancer Conference: Advancements in Treatment & Technology. Tyler, TX, US.
- 2016. Immunotherapeutic Approaches in Prostate Cancer, Community Engagement Speaker. Tex Us Too. Houston, TX, US.
- 2016. Immunotherapeutic Approaches in Prostate Cancer – Why Now?. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Immune Checkpoints: Role in Prostate Cancer Progression & Candidates for Therapeutic Targets. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Anti-CTLA-4 Immunotherapy in Prostate Cancer. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Immune Checkpoints: Role in Prostate Cancer Progression & Candidates for Therapeutic Targets. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Immune Checkpoint Therapies: Managing Side Effects. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Targeting Immune Checkpoints in Genitourinary Malignancies. Visiting. 11th Annual MD Anderson- Physicians Network Symposium. Houston, TX, US.
- 2015. Managing Symptoms and Communicating with Your Healthcare Team. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Anti-CTLA-4 Immunotherapy in Prostate Cancer. Conference. Baylor College of Medicine / MD Anderson Cancer Center Joint Symposium. Houston, TX, US.
- 2014. Immunobiology of Bone & Interaction with Androgen Signaling. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Targeting CTLA-4 and the AR Signaling Pathway in Prostate Cancer. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Immune Checkpoint Blockade in Prostate Cancer Therapy. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Immune Checkpoint Blockade in Prostate Cancer Therapy. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2018. Immunotherapy in Prostate Cancer: Promises and Pitfalls. Invited. Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Castrate Resistant Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Cancer). Houston, TX, US.
National Presentations
- 2024. Current Uses of Immunotherapy in Prostate Cancer Immunotherapy and Prostate Cancer: What’s Now, What’s Next. Invited. Webinar, US.
- 2024. Relevance of Human Models or Immunotherapy-Related Toxicities. Panelist. 2024 IOTOX Symposium. Houston, Texas, US.
- 2024. Future Directions in Systemic Therapy for Prostate Cancer. Invited. 2nd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, TX, US.
- 2024. Identifying Mechanistic Biomarkers of Response to Novel T Cell Bispecifics in Metastatic Castration-Resistant Prostate Cancer. Invited. 15th Annual Prostate Cancer SPORE Retreat. Los Angeles, CA, US.
- 2024. Clinical Trials in Advanced Prostate Cancer. Virtual, US.
- 2024. Overcoming Immunotherapy Resistance in Prostate Cancer. Invited. 20th Oncology Updates: Advances and Controversies. Steamboat Springs, CO, US.
- 2023. The Biology and Rationale for PSMAxCD28 in Prostate Cancer. Invited. 6th Annual Summit on Genitourinary Malignancies. Colorado Springs, CO, US.
- 2023. The Role of Cabozantinib as a Microenvironment Modulator. Invited. 6th Annual Summit on Genitourinary Malignancies. Colorado Springs, CO, US.
- 2023. IC Inhibitors –Targeting Immune Checkpoints (MMR loss/MSI-high). Invited. UroToday. Virtual, US.
- 2023. PSMAxCD28 T Cell Bispecific + Anti-PD-1: A Single-Institution Experience. Invited. Fall Retreat. Montecito, CA, US.
- 2023. T Cell Bispecifics in Prostate Cancer & Hallmarks of ICT-Induced Myocarditis and Myositis. Invited. Spring Retreat. Kauai, HI, US.
- 2023. De Novo Oligometastasis: Systemic Therapy. Invited. Christopher G Wood Advances in Urologic Oncology Symposium. Austin, TX, US.
- 2023. Immunotherapeutic Strategies. Invited. Dendreon. Atlanta, GA, US.
- 2023. Immunotherapy for Prostate Cancer: Can We Make a "Cold" Tumor "Hot". Invited. 19th Oncology Updates: Advances and Controversies. Houston, TX, US.
- 2022. A Path Forward to Maximizing Efficacy and Minimizing Toxicities to Immunotherapies. Visiting. 3rd Annual IOTOX Research Retreat. Houston, TX, US.
- 2022. Rationally-Based Immunotherapy Strategies to Overcome the Immunosuppressive Prostate Tumor Microenvironment. Invited. Prostate Cancer SPORE Investigator Monthly Meeting. Virtual, US.
- 2022. Background on Current Mechanistic Understanding of Common Toxicities. Invited. Advances in Cancer Immunotherapy: A Focus on Toxicity Management. Houston, TX, US.
- 2022. Immunotherapy in Prostate Cancer: Overcoming the Immunosuppressive Prostate Bone Tumor Microenvironment. Invited. Pan-Prostate SPORE Meeting. Los Angeles, CA, US.
- 2021. Anti-CTLA-4 Therapy in Prostate Cancer. Invited. Symposium on Immuno-Oncology in Prostate Cancer. Virtual, US.
- 2020. Phase 1b/2, Open-Label, Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Participants with Metastatic Castrate Resistant Prostate Cancer (ARC-6). Invited. Medscape Oncology. Virtual, US.
- 2020. IO Approaches for Prostate Cancer Breakout Session. Invited. The Future of Prostate Cancer Therapy, Scientific & Partnering Virtual Event. Virtual, US.
- 2020. Myeloid Cells in the TME. Invited. Fall Retreat. Virtual, US.
- 2020. Prostate Cancer and Immunotherapy Breakout Session. Invited. Summit. Virtual, US.
- 2020. Targeting the Immunosuppressive Prostate Tumor Microenvironment. Invited. Multi-Institutional Prostate Cancer Program Retreat. Fort Lauderdale, FL, US.
- 2019. Immune Checkpoint Therapies in Prostate Cancer, CA209-650: Nivolumab North America Investigator Meeting. Invited. Bristol-Myers Squibb. Philadelphia, PA, US.
- 2018. The Role of Immunotherapy in Prostate Cancer. Invited. 13th Update on the Management of Genitourinary Malignancies. Houston, TX, US.
- 2017. Immunotherapy in Genitourinary Cancers Balancing Toxicity with Efficacy. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Overview of Immuno-Oncology in Bladder and Prostate Cancers. Invited. Cancer Research Institute (CRI) & Parker Institute for Cancer Immunotherapy (PICI). New York, NY, US.
- 2016. The Role of Immunotherapy in the Treatment of Prostate Cancer. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Immunotherapeutic Approaches for Prostate Cancer. Invited. 2nd Annual Spring Cactus Cancer Conference. Scottsdale, AZ, US.
- 2015. Immunotherapy for the Treatment of Genitourinary Malignancies. Invited. Advances in Cancer Immunotherapy. Houston, TX, US.
International Presentations
- 2024. Strategies to Overcome the Immunosuppressive Prostate Tumor Microenvironment. Invited. 12th Congress of the Federation of African Immunology Societies 2024 (FAIS-2024). Cotonou, BJ.
- 2024. Turning Immune Cold Tumors Hot: Lessons Learned from Immunotherapy in Prostate Cancer. Invited. 9th International Adrenal Cancer Symposium. Houston, US.
- 2024. Immunotherapy for Urologic Tumors. Invited. 2024 Sino-US Academic Workshop on Genitourinary Cancer Immunotherapy Program. Shanghai, CN.
- 2024. Prostate Cancer as a Paradigm of IO Resistance. Invited. VIII Siena I-O Think Tank. Siena, US.
- 2024. IO Strategies to Overcome the Immunosuppressive Prostate Tumor Microenvironment. Invited. Annual Meeting, Keynote Speaker. Brandenburg, DE.
- 2024. Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC). Poster. Genitourinary Cancers Symposium. San Francisco, US.
- 2024. The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Poster. Genitourinary Cancers Symposium. San Francisco, US.
- 2024. LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Poster. Genitourinary Cancers Symposium. San Francisco, US.
- 2023. Threading the Needle Between Efficacy and Toxicity with CD28xPSMA Bispecific. Invited. 30th Annual Scientific Retreat. Carlsbad, US.
- 2023. TME Heterogeneity at Different Metastatic Sites. Invited. VII-Siena I-O Think Tank. Siena, IT.
- 2023. Novel targets and mechanisms: Looking beyond the AR-axis. Invited. Merck. Virtual, US.
- 2023. Path Forward for Immune Checkpoint Therapies. Invited. The Prostate Cancer Clinical Masterclass Series. Virtual, US.
- 2022. Rationally-Based Immunotherapy Strategies to Overcome the Immunosuppressive Prostate Bone Tumor Microenvironment, Breakout Session: Critical Pathways for Response. Invited. Fall Retreat. Montecito, US.
- 2022. Novel Targets/Combinations that Did Not Fulfill the Promises: A Vision of I-O. Invited. VI-Siena I-O Think Tank. Siena, IT.
- 2021. PD-1 Resistance in Solid Tumors. Invited. V Siena I-O Think Tank. Siena, IT.
- 2021. Immunotherapies in Prostate Cancer. Invited. Institutional Perspectives in Cancer: Prostate Cancer. Virtual.
- 2021. ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC). Poster. 2021 Annual Meeting. Virtual, US.
- 2021. Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC). Poster. 2021 Annual Meeting. Virtual, US.
- 2020. Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment. Invited. Immuno-Oncology Keynote Speaker. Webinar, US.
- 2020. Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment. Invited. Frontiers in Cancer Immunotherapy 2020. Webinar, US.
- 2020. Advances in Prostate Cancer Immunotherapy. Visiting. 2019 Global Academic Programs (GAP) Conference. Houston, US.
- 2019. A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). Invited. AstraZeneca. Arlington, US.
- 2019. Immunotherapy in Prostate Cancer. Invited. 3rd Annual Global Summit on Genitourinary Malignancies. Banff, CA.
- 2019. Overcoming the Immunosuppressive Prostate Tumor Microenvironment. Invited. 2019 International Cancer Immunotherapy Conference. Paris, FR.
- 2019. Immune Checkpoint Therapies in Prostate Cancer CA209-650. Invited. Nivolumab Europe Investigator Meeting. Rome, IT.
- 2019. A Phase Ib/II Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-resistant Prostate Cancer. Poster. 2019 Annual Meeting. Chicago, US.
- 2019. Immunotherapy in Prostate Cancer. Invited. Updates in Oncology. Iasi, RO.
- 2019. Immune Checkpoint Therapies in Prostate Cancer. Invited. Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit. Whistler, CA.
- 2018. Overcoming the Immunosuppressive Tumor Microenvironment in Prostate Cancer. Invited. Coffey-Holden Prostate Cancer Academy. Los Angeles, US.
- 2017. Role of Immunotherapies in Prostate Cancer. Invited. Prostate Cancer International Conference. Houston, GR.
- 2016. Rationally Developing Immunotherapy Strategies in Prostate Cancer. Invited. 23rd Annual Scientific Retreat. Carlsbad, US.
- 2016. Exploratory Biomarkers that Predict for Clinical Outcomes in a Phase II Trial with Ipilimumab Plus Finite Androgen Deprivation Therapy for Metastatic Non-castrate Prostate Cancer. Poster. 2016 Annual Meeting. New Orleans, US.
- 2015. Immune Correlates in a Phase II Clinical Trial with Ipilimumab in Combination with Finite Androgen Deprivation Therapy in Patients with Metastatic Non-castrate Prostate Cancer. Poster. 30th Annual Meeting. National Harbor, US.
- 2015. Finite Androgen Deprivation Therapy (ADT) Plus Ipilimumab (IPI) in Metastatic Non-Castrate Prostate Cancer. Poster. 22nd Annual Scientific Retreat. Washington, US.
- 2015. New Methodology in Immunotherapy Clinical Trial. Invited. Immuno-Oncology Conference. San Juan, US.
- 2015. Advances in Predictive Biomarkers in Immuno-Oncology, Basic and Clinical Advances in Immuno-Oncology. Invited. Immuno-Oncology Conference. San Juan, US.
- 2014. Identifying and Designing Agents Targeting Novel Immune Checkpoints. Invited. 25th Annual Antibody Engineering & Therapeutics Conference and Exhibition. Huntington Beach, US.
- 2014. Anti-CTLA-4 Immunotherapy in Prostate Cancer. Invited. 21st Annual Scientific Retreat. Carlsbad, US.
- 2014. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in men with hormone-naïve metastatic prostate cancer (HN-mPCa). Poster. Congress 2014. Madrid, US.
- 2014. Targeting Immune Checkpoints in Prostate Cancer. Invited. Coffey-Holden Prostate Cancer Academy. La Jolla, US.
- 2014. Immunotherapy Strategies in Genitourinary Malignancies. Invited. Cancer Research Institute (CRI). New York, US.
- 2014. Immunotherapy Strategies in Genitourinary Malignancies. Invited. ION Solutions Emerging Therapies. Atlanta, US.
- 2013. Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer. Poster. 2013 Annual Meeting. Chicago, US.
- 2013. Dissecting the therapeutic effects of anti-CTLA and ADT in a murine hormone-sensitive prostate cancer. Poster. Genitourinary Cancers Symposium. Orlando, US.
Formal Peers
- 2025. Development of a Grant/Translational Idea and Career Development Awards. Invited. 2025 Cancer Immunotherapy Winter School. Austin, TX, US.
- 2025. Immunotherapeutic Strategy: Immune Checkpoint Blockade. Invited. 2025 Cancer Immunotherapy Winter School. Austin, TX, US.
- 2024. Current Uses of Immunotherapy in Prostate Cancer. Houston, Texas, US.
- 2024. Modulating the Tumor Microenvironment with T Cell Bispecifics. Houston, Texas, US.
- 2024. Development of a Grant/Translational Idea and Career Development Awards. Invited. Cancer Immunotherapy Winter School. Austin, TX, US.
- 2024. Immunotherapeutic Strategy: Immune Checkpoint Blockade. Invited. Cancer Immunotherapy Winter School. Austin, TX, US.
- 2023. Modulating the Tumor Microenvironment with T Cell Bispecifics. Invited. Primer on Tumor Immunology and Cancer Immunotherapy. San Diego, CA, US.
- 2023. Development of Grant / Translational Idea. Austin, Texas, US.
- 2023. Immunotherapeutic Strategy: Immune Checkpoint Blockade. Invited. Cancer Immunotherapy Winter School,. Austin, TX, US.
- 2022. Modulating the Tumor Microenvironment with Bispecifics. Invited. Primer on Tumor Immunology and Cancer Immunotherapy. Boston, MA, US.
- 2022. Development of Grant / Translational Idea. Invited. Cancer Immunotherapy Winter School. Austin, TX, US.
- 2022. Immunotherapeutic Strategy: Immune Checkpoint Blockade. Virtual, US.
- 2021. Immunotherapeutic Strategy: Immune Checkpoint Blockade. Invited. Cancer Immunotherapy Winter School. Virtual, US.
- 2021. Development of a Translational Idea. Invited. Cancer Immunotherapy Winter School. Virtual, US.
- 2020. Development of a Translational Idea. Invited. Cancer Immunotherapy Winter School. Houston, TX, US.
- 2020. Immunotherapeutic Strategy: Immune Checkpoint Blockade. Invited. Cancer Immunotherapy Winter School. Houston, TX, US.
- 2019. Management of IO Toxicities: MDACC Strategy. Invited. IO Practicum. Houston, TX, US.
- 2019. Immunotherapeutic Strategy: Immune Checkpoint Blockade. Invited. Cancer Immunotherapy Winter School. Mesa, AZ, US.
- 2018. Basics of Immunotherapy. Invited. 2019 Advances in Cancer Immunotherapy. Houston, TX, US.
- 2016. Successfully Integrating Immunotherapies in Advanced Prostate Cancer. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Immune Checkpoint Therapies: Managing Side Effects. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Innovative Clinical Trial Designs for Immune Monitoring. Invited. Primer on Tumor Immunology and Cancer Immunotherapy. National Harbor, MD, US.
- 2015. Evaluation and Management of Immune-related Adverse Events to Immune-modulating Agents. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Prostate Cancer and Immune Environment. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Immunotherapy in CRPC Management. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Tumor Immunology: Past, Present and Future. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Grant & Contract Support
| Date: | 2024 - 2025 |
| Title: | Priority Project 1: Targeting Myeloid Cells in Lethal Prostate Cancer to Overcome the Immunosuppressive Microenvironment |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Collaborator |
| ID: | Prostate Moon Shot |
| Date: | 2024 - 2029 |
| Title: | Targeting Immunosuppressive Myeloid Cells via the TGF-beta and VISTA Pathways to Overcome Resistance to Immune Checkpoint Therapies in Metastatic Castrate-Resistant Prostate Cancer to Bone |
| Funding Source: | NIH/NCI |
| Role: | Clinical Co-Leader |
| ID: | P50 CA288272-01 |
| Date: | 2024 - 2027 |
| Title: | Dissection of CAMKK2’s Tumor Cell-Intrinsic And -Extrinsic Roles in Prostate Cancer |
| Funding Source: | CPRIT |
| Role: | Collaborator |
| ID: | RP240072 |
| Date: | 2023 - 2030 |
| Title: | 2023-0589: A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer |
| Funding Source: | MacroGenics, Inc |
| Role: | PI |
| ID: | NCT05848011 |
| Date: | 2023 - 2030 |
| Title: | 2023-0135: SIV / OTC 2023-0135: A Pilot Presurgical Trial of REGN5678 (Anti-PSMAxCD28) In Patients with High-Risk, Localized Prostate Cancer Followed by Radical Prostatectomy |
| Funding Source: | Regeneron Pharmaceuticals |
| Role: | PI |
| ID: | NCT06085664 |
| Date: | 2023 - 2030 |
| Title: | 2023-0187: Phase I/II First-in-Human Study of TT-10 as a Single Agent in Participants with Advanced Selected Solid Tumors |
| Funding Source: | Tarus Therapeutics, LLC |
| Role: | PI |
| ID: | NCT04969315 |
| Date: | 2023 - 2024 |
| Title: | Prostate Moon Shot, PP1: Myeloid-Targeting strategies to overcome the immunosuppressive tumor microenvironment of lethal prostate cancer |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Clinical Leader |
| ID: | Prostate Cancer Moon Shot |
| Date: | 2023 - 2024 |
| Title: | Prostate Moon Shot, PP3: Linking one-carbon metabolism to lineage promiscuity in aggressive variant prostate cancers (AVPC) |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Clinical Leader |
| ID: | Prostate Cancer Moon Shot |
| Date: | 2022 - 2023 |
| Title: | Prostate Moon Shot, PP3: Development of Bispecific Immunotherapy Strategies to Overcome the Immunosuppressive Prostate Tumor Microenvironment (Subudhi/Sharma) |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Co-Leader |
| ID: | Prostate Cancer Moon Shot |
| Date: | 2022 - 2029 |
| Title: | A Phase 2 Trial of BMS-986218 or BMS-986218/Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (2021-1006) |
| Funding Source: | Bristol-Myers Squibb |
| Role: | PI |
| ID: | NCT05169684 |
| Date: | 2020 - 2027 |
| Title: | A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2020-0568) |
| Funding Source: | Amgen Inc |
| Role: | PI |
| ID: | NCT04631601 |
| Date: | 2020 - 2025 |
| Title: | Chemoimmunotherapy for Aggressive Variant Prostate Cancers (AVPC) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH-20-1-0257 (PC190353) |
| Date: | 2020 - 2023 |
| Title: | PC190355 - Prostate cancer tryptophan metabolism alters the immune microenvironment and promotes aggressive variant phenotype |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Collaborator |
| Date: | 2020 - 2027 |
| Title: | A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Prostate Cancer (2020-0376) |
| Funding Source: | Arcus Biosciences |
| Role: | PI |
| ID: | NCT04381832 |
| Date: | 2020 - 2027 |
| Title: | Advance Funding-Rapid Activation Program-2020-0072-A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer, protocol number CA209-7DX (2020-0072) |
| Funding Source: | Bristol-Myers Squibb |
| Role: | PI |
| ID: | NCT04100018 |
| Date: | 2019 - 2026 |
| Title: | A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration resistant Prostate Cancer (2019-0140) |
| Funding Source: | Parker Institute for Cancer |
| Role: | PI |
| ID: | NCT03835533 |
| Date: | 2019 - 2020 |
| Title: | Flagship 2: Development of Rational Immunotherapy Combinations to Overcome the Immunosuppressive Prostate Tumor Microenvironment |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Co-Leader |
| ID: | Prostate Cancer Moon Shot |
| Date: | 2018 - 2019 |
| Title: | Flagship 1: Development of Mechanism-based Combination Therapies for Castration-resistant Prostate Cancer Subproject: Targeting the Immunosuppressive Compartment of the Prostate Cancer Bone Metastatic Microenvironment to Improve Clinical Outcomes (Subudhi/Wang) |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Subproject Co-Leader |
| ID: | Prostate Cancer Moon Shot |
| Date: | 2018 - 2022 |
| Title: | Targeting the Immunosuppressive Compartment of the Prostate Cancer Bone Metastatic Microenvironment to Improve Clinical Outcomes |
| Funding Source: | V Foundation/Lloyd Family Clinical Oncology Scholar Award |
| Role: | PI |
| ID: | D2018-014 |
| Date: | 2017 - 2020 |
| Title: | RFA IO Combinations |
| Funding Source: | Janssen Research & Development, LLC |
| Role: | Co-I |
| Date: | 2017 - 2018 |
| Title: | Flagship 2: Targeting Immune Tumor-Associated Microenvironment in Prostate Cancer |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Co-I |
| ID: | Prostate Moon Shot |
| Date: | 2016 - 2023 |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE – Project 1: Integrating Ipilimumab Immunotherapy with Approved Treatment Strategies in CRPC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA140388-8 |
| Date: | 2015 - 2016 |
| Title: | Targeting the Immune & Non-immune Tumor-associated Microenvironments in Prostate Cancer |
| Funding Source: | UT MD Anderson Cancer Center - Prostate Cancer Moon Shot |
| Role: | Co-I |
| ID: | Prostate Cancer Moon Shot |
| Date: | 2015 - 2017 |
| Title: | A Feasibility Study to Determine T-Cell Responses to Neoantigens Following Treatment with Ipilimumab in Men with Metastatic Castration-Resistant Prostate Carcinoma (2014-0444) |
| Funding Source: | HI-CRSP |
| Role: | Co-I |
| ID: | 2013-0444 |
| Date: | 2014 - 2018 |
| Title: | Improving Patient Selection for Immune Checkpoint Therapy: Maximizing Benefit and Minimizing Toxicities |
| Funding Source: | Prostate Cancer Foundation |
| Role: | PI |
| ID: | Young Investigator Award |
| Date: | 2011 - 2013 |
| Title: | National Institute of Health Clinical Scholars Biomedical Research Training Program |
| Funding Source: | NIH/NCI |
| Role: | Research Fellow |
| ID: | 5T32CA009512 |
Patient Reviews
CV information above last modified April 22, 2025